alexa Safety Modality for X-linked Severe Combined Immunodeficiency Gene Therapy | OMICS International | Abstract
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Safety Modality for X-linked Severe Combined Immunodeficiency Gene Therapy

Nicole Scheumann1,3,#, Elisa Kieback1# and Wolfgang Uckert1,2*

1Max-Delbrueck-Center for Molecular Medicine, Robert-Roessle-Strasse 10, D-13092 Berlin, Germany

2Humboldt-University of Berlin, Institute of Biology, Robert-Roessle-Strasse 10, D-13092 Berlin, Germany

3Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, United Kingdom

#N.S. and E.K. contributed equally to this work

*Corresponding Author:
Wolfgang Uckert
Max-Delbrueck-Center for Molecular Medicine
Robert-Roessle-Strasse 10, D-13092 Berlin, Germany
Tel: +49-30-94063196
Fax: +49-30-94063306 E-mail: [email protected]

Received date: March 15, 2012; Accepted date: April 16, 2012; Published date: April 18, 2012

Citation: Scheumann N, Kieback E, Uckert W (2012) Safety Modality for X-linked Severe Combined Immunodeficiency Gene Therapy. J Cell Sci Ther 3:121. doi: 10.4172/2157-7013.1000121

Copyright: © 2012 Scheumann N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

X-linked severe combined immunodeficiency (SCID-X1), caused by a defect of the cytokine receptor common gamma chain (γc), has been successfully treated by gene therapy in the clinic. However, the occurrence of leukemia in several patients preceded by loss of oligoclonality revealed that treatment is associated with a risk inherent to the genetic modification of hematopoietic stem cells. In this study, we developed a safety approach that allows the specific elimination of gene-modified cells. For this, a small peptide sequence (myc-tag) was introduced into the murine γc protein. Cells expressing the modified chain can be detected with a myc-specific antibody by flow cytometry and are effectively depleted in vitro in the presence of complement factors. Further, thymic-derived T cells from mice reconstituted with myc-tagged γc-transduced bone marrow stem cells can be depleted by antibody administration in vivo. Similarly, specific complement-mediated lysis was observed for human T cells expressing the human myc-tagged γc. In a cell proliferation assay, the modified cytokine receptor chain showed no functional impairment compared to the wild-type chain. In sum, we show proof-of-principle of a safety mechanism for SCID-X1 gene therapy that would allow elimination of gene-corrected cells in a patient upon observation of monoclonal outgrowth.

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version